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CC BY-NC-ND license (http://creativeAbstract Polycystic ovary syndrome (PCOS) is an endocrine disorder which affects 6.6% of
women of child-bearing age. Although olfactory dysfunction is frequent in the population
and it negatively affects quality of life, neither physicians or patients consider this important.
This case-control study included 30 patients diagnosed with PCOS, and 25 healthy age-matched
controls. Sniffin’ sticks tests (BurghartGmbH, Wedel, Germany) were used to analyze olfactory
functions, and the Beck Depression Inventory was used to evaluate depressive symptoms. The
total odor score was significantly lower in the PCOS group compared to the control group
(p< 0.005). The Beck depression score was higher in the PCOS group (p< 0.005). There was
a negative correlation between the total odor score and the Beck Depression Score. Patients
with PCOS have impaired olfactory function. This might be related to depressive disorders that
are also observed in those patients.
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Polycystic ovary syndrome (PCOS) is an endocrine disorder,
which is characterized by ovulatory dysfunction, hyper-
androgenism and infertility, and it affects 6.6% of women at
child-bearing age [1]. PCOS is associated with hypertension,
dyslipidemia, insulin resistance and impaired glucose
tolerance or type 2 diabetes mellitus, which are compo-
nents of the metabolic syndrome [2e5]. Diagnosis of PCOS
is established according to revised Rotterdam Criteria, in
the presence of two out of three of the following features:
oligo-anovulation, clinical and/or biochemical signs of
hyperandrogenism, and polycystic ovaries [6].
In addition to well-defined clinical manifestations of
PCOS, other clinical manifestations such as sleep disorders,
mood symptoms and eating disorders may also be seen in
patients with PCOS [7e12]. The olfactory system can be
involved in many disease states including some neurode-
generative and endodocrine disorders.
Due to a close neuroanatomical connection between
odor and emotional processing, the relationship between
odor function and depression has lately attracted atten-
tion. Recent studies have shown that olfactory function was
impaired in the case of major depression [13,14].
The aim of this study was to test the null hypothesis that
olfactory function is different in patients with PCOS
compared to women without PCOS.
Material and methods
This case-control study was conducted between June 2015
and November 2015 in the Department of Obstetrics and
Gynecology, Mugla Sıtkı Koc¸man University, Mugla, Turkey.
Mugla Sıtkı Koc¸man University Ethics Committee approved
the study protocol. Informed consents were obtained from
all participants before starting the study. Thirty volunteer
patients diagnosed with PCOS according to Rotterdam
criteria (2003 revised Rotterdam criteria), and 25 age-
matched healthy volunteers with regular menses were
included in the study. Exclusion criteria were history of
neurodegenerative diseases, obstructive nasal disorders,
obesity, insulin resistance, smoking, and use of
antidepressants.
All participants completed the Beck Depression In-
ventory consisting of 21 questions. Each question was
scored between 0 and 3. The minimum score was 0, and the
maximum score was 63. All participants had otorhinolar-
yngological examinations. The olfactory function test
(Sniffin’ Stick odor test; BurghartGmbH) was performed by
the same otorhinolaryngologist. Odor threshold, discrimi-
nation and identification (TDI) scores were determined.
Odor threshold test
The odor threshold (OT) was determined using n-butanol. A
staircase procedure was used. After a start concentration
of the smell was determined, the dilution at which the
smell could just be distinguished from nonsmelling pens was
identified. The lowest available odor concentration was
determined as the mean of the last four from a total of
seven staircase reversals.Odor discrimination test
The odor discrimination (OD) was determined between two
different odorants using 16 triplet pens. The subject was
presented with three pens; two contained the same
odorant and one was different. The patient was asked to
find the different odorant. Presentation of triplets was
separated by at least 30 seconds. The score which ranged
between 0 and 16 was the sum score of the correctly
identified pens.
Odor identification test
Sixteen common odors with four choices were presented in
the odor identification (OI) test. Subjects were free to
sample the odors as often as necessary to make a decision.
Total score ranged between 0 and 16.
TDI score
The sum of TDI scores was defined as the total odor score.
Subjects with a TDI score > 30 were considered to have a
normal olfactory function (normosmia); subjects with a TDI
score of 15e30 were considered to have decreased olfac-
tory function (hyposmia); and subjects with a TDI score <
15 were considered to have loss of olfactory function
(anosmia).
The Statistical Package for Social Sciences (SPSS, Chi-
cago, IL) for Windows, version 17.0 program was used for
statistical analysis. Normality of data distribution was
tested with the Kolmogorov-Smirnov test. The differences
between the means of the variables were tested with two
independent sample t tests if the distribution of the vari-
ables were normal. The Mann-Whitney U test was used if
the distribution of the variables was not normal. Pearson
correlation analysis was used to test the correlation be-
tween the TDI and Beck depression scores. The significance
level was set at p< 0.05.
Results
The study and the control groups were similar for follicle
stimulating hormone and estradiol levels. Luteinizing hor-
mone levels were significantly higher in the PCOS group.
Analysis of olfactory functions revealed that OT, OD, and
OI scores were lower in the PCOS group when compared to
the control group, but the differences were not statistically
significant. The TDI score was significantly lower in the
PCOS group (pZ 0.001). The Beck Depression Score was
significantly higher in the PCOS group (Table 1). None of the
participants in the PCOS or control groups had hyposmia or
anosmia.
Correlation analysis of the Beck Depression Score and
TDI revealed a statistically significant negative correlation
(p< 0.005, rZe0.675) (Figure 1).
Discussion
In this study, we found significantly impaired olfactory
function in patients with PCOS when compared to the
Table 1 Demographic and clinical characteristics of the
patients.
PCOS group
(nZ 30)
Control group
(nZ 25)
p
Age (years)a 24.13 0.01 28.5 7.8 0.063
LH (mIU/mL)a 11.8 5.0 5.4 0.5 0.001*
FSH (mIU/mL)b 6.3 (2.5e10) 6.1 (4.1e7.3) 0.422
E2 (pg/mL)a 60.3 23.7 51.6 11.4 0.096
OTa 7.3 2.2 7.4 1.8 0.388
ODa 12.2 2.5 13.4 2.2 0.480
OIa 12.1 1.8 13.5 1.7 0.808
TDIb 32.5
(20.5e41.5)
34.25
(29.25e39.5)
0.034*
BECK scorea 18.7 4.1 9.2 1.3 0.003*
E2Z estradiol; FSHZ follicle stimulating hormone; LHZ lu-
teinizing hormone; ODZ odor discrimination; OIZ odor iden-
tification; OTZ odor threshold; TDIZ threshold,
discrimination, identification score.
a Values expressed in mean standard deviations.
b Values expressed in medians with minimum and maximum
values.
Figure 1. The correlation analysis of olfactory functionwith Beck depression score. BECKZ Beckdepression score; TDIZ threshold,
discrimination, identification score.
Olfactory function in PCOS 315control group. In addition, we found a negative correlation
between the Beck Depression Inventory Score and olfactory
function.
Although it is encountered frequently, olfactory
dysfunction is not considered important either by the pa-
tients or the physicians. Various disorders may cause an
underlying condition of olfactory dysfunction. Infectious,
metabolic, neurological, endocrine, and psychiatric factorsas well as nasal disorders may cause olfactory dysfunction.
In this study, we aimed to analyze olfactory function, and
its association with depressive symptoms in PCOS, which is
a frequent endocrinological disorder seen in women at
reproductive ages, usually accompanied by mood disorders.
The exact etiology of this heterogeneous, multisystemic
condition is still unknown. It was found that psychiatric
disorders including depression, anxiety disorder, low self-
esteem, and psychosexual dysfunction were more frequent
in patients with PCOS [11,15,16]. Hirsutism, acne, irregular
menses, infertility, and obesity which may be seen in PCOS
usually result in negative feelings. Therefore, the risk for
psychiatric symptoms increases. The prevalence of obesity
is approximately 42% in PCOS, and a number of studies
showed a biopsychosocial relationship between obesity and
depression [1,17e19]. In addition, a positive correlation
was found between depressive symptoms and obesity in
patients with PCOS [20]. In this study, we excluded patients
with a body mass index > 30 kg/m2 and a homeostasis
model assessment of insulin resistance  2.5 because
obesity, possible accompanying insulin resistance and dia-
betes, and resulting neuropathy could be possible causes
for olfactory dysfunction.A number of studies showed that there was an associa-
tion between olfactory disorders and major depressive
episodes [13,14,21]. Neuroradiological studies indicated
that close proximity could be a factor [22]. In addition,
behavioral, endocrine and immunological parameters, as
well as neurotransmitters of the rats that had olfactory
bulbectomy, were found to be similar to those of the rats in
depression, and olfactory bulbectomy was used as an
316 S.B. Koseoglu et al.experimental depression model [23,24]. On the other hand,
a reciprocal association was found between depression and
olfactory functions: olfactory dysfunction deteriorates
quality of life, and depression deteriorates olfactory func-
tion [25,26].
In this study, the Beck Depression Score was found to be
significantly higher in the PCOS group when compared to
the controls. The Beck Depression Inventory was published
in 1961, and translated into Turkish in 1989. It is a valid and
reliable scale. It measures physical, emotional, cognitive,
and motivational symptoms of depression. It is not used to
diagnose depression, but to measure the severity of the
depressive symptoms.
Small sample size and lack of correlation between lab-
aratory data of patients and olfactory funtion were the
important limitations of our study. We think olfactory
function tests may be useful adjunct for the determination
of disease severity and the response to treatment, and may
inspire further studies.
In conclusion, in this study we analyzed olfactory func-
tions in PCOS for the first time in English literature, and
found that olfactory functions were impaired in the PCOS
group. The tendency for depression in PCOS may be one
reason for impaired olfactory function, but some other
undetermined factors may also play a role. Further studies
on larger patient cohorts are needed to verify our findings.References
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